“We think Leno will bring greater discipline to the Boston Scientific’s P&L, but it will probably take some time for this to play out.”. The Company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, and neuromodulation. “He has been instrumental to our growth strategy, particularly the historic and transforming acquisition of Guidant, which I believe has been our most important and beneficial transaction,” said Tobin, in a statement. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. When he departs in July, Best will be succeeded by Sam Leno, currently CFO and executive vice president of finance and corporate services for Zimmer Holdings Inc. At Boston Scientific, he will be CFO and executive vice president of finance and information systems. The Company will immediately begin to execute a new set of restructuring initiatives designed to improve its effectiveness and efficiency. Your email address will not be published. The company could also raise money by selling its stakes in Aspect Medical ASPM.O and Cyberonics CYBX.O. The Presidents of Japan, Europe (including a consolidated Shared Services team) and the newly formed Emerging Markets Group will report directly to the CEO. Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. Boston Scientific's Executive Committee and Board Of Directors are focused on high performance to benefit patients, clinicians and shareholders. Mr. Neumann will oversee and be accountable for all the Company's restructuring and integration activities, including the combination of the Cardiovascular Group and the Cardiac Rhythm Management Group. Best was seen as a key player in the medical device maker’s $27-billion acquisition of Guidant Corp. last year, and is credited with engineering 37 acquisitions during his tenure, according to the Boston Globe. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. Senior VP/Corporate Controller, Boston Scientific Corp, Boston Scientific Said to Put Snake Venom Unit Up for Sale, Boston Scientific Plans Ventilator at About 5% of Rivals’ Price. He could be the right person to do that. Kaitlyn Donovan. He said he was encouraged that Boston Scientific had resolved some issues with the U.S. Food and Drug Administration and hoped it follows through with a potential sale or spinoff of its endosurgery business. Key components of the management changes and restructuring initiatives include: In addition, the Company announced the following management changes: "These changes to date bring together an outstanding group of seasoned leaders, with a broad range of talents and abilities and a proven history of delivering results and achieving objectives," said Elliott. "The Company and all its stakeholders stand to benefit considerably from their collective knowledge, experience and expertise. NATICK, Mass., Feb. 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced a series of management changes and restructuring initiatives designed to strengthen the Company and position it for long-term success. The company could also raise money by selling its stakes in Aspect Medical. Since joining Boston Scientific in 2007, Mr. Leno has served as Executive Vice President of Finance and Information Systems and Chief Financial Officer. Jeffrey Capello, Boston Scientific’s executive vice president and chief financial officer, will transition out of the role effective December 31, 2013. Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. He has served as chief legal officer since December 2005. Mr. Kucheman most recently served as President of the Cardiovascular Group. These changes were, in part, designed to allow me to spend more time with our operating divisions and international regions, as we place greater emphasis on stimulating sales growth, assessing our business portfolio opportunities and expanding operating profit margins.". Mr. Colen most recently served as President of the Cardiac Rhythm Management Group. Added Thrivent’s Heupel: “Back in the early 1990s, people thought this company wouldn’t make it. See here for a complete list of exchanges and delays.
He joined Boston Scientific in 1991 as a territory manager before assuming management-level positions of increasing responsibility.